RT Journal Article
SR Electronic
T1 Epidemic Trend Analysis of SARS-CoV-2 in SAARC Countries Using Modified SIR (M-SIR) Predictive Model
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.29.20142513
DO 10.1101/2020.06.29.20142513
A1 Samrat Kumar Dey
A1 Md. Mahbubur Rahman
A1 Kabid Hassan Shibly
A1 Umme Raihan Siddiqi
A1 Arpita Howlader
YR 2020
UL http://medrxiv.org/content/early/2020/06/30/2020.06.29.20142513.abstract
AB A novel coronavirus causing the severe and fatal respiratory syndrome was identified in China, is now producing outbreaks in more than two hundred countries around the world, and became pandemic by the time. In this article, a modified version of the well known mathematical epidemic model Susceptible (S)- Infected (I)- Recovered (R) is used to analyze the epidemic’s course of COVID-19 in eight different countries of the South Asian Association for Regional Cooperation (SAARC). To achieve this goal, the parameters of the SIR model are identified by using publicly available data for the corresponding countries: Afghanistan, Bangladesh, Bhutan, India, the Maldives, Nepal, Pakistan and Sri Lanka. Based on the prediction model we estimated the epidemic trend of COVID-19 outbreak in SAARC countries for 20 days, 90 days, and 180 days respectively. An SML (short-mid-long) term prediction model has been designed to understand the early dynamics of COVID-19 Epidemic in the south-east Asian region. The maximum and minimum basic reproduction number (R0 = 1.33 and 1.07) for SAARC countries are predicted to be in Pakistan and Bhutan. We equate simulation results with real data in the SAARC countries on the COVID-19 outbreak, and model potential countermeasure implementation scenarios. Our results should provide policymakers with a method for evaluating the impacts of possible interventions, including lockdown and social distancing, as well as testing and contact tracking.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not ApplicableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNot Applicable